HSBC says this biopharma company can jump 25% despite 'patent cliff'

  • 📰 CNBC
  • ⏱ Reading Time:
  • 5 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 5%
  • Publisher: 72%

Indonesia Berita Berita

Indonesia Berita Terbaru,Indonesia Berita utama

HSBC initiated coverage on the drug treatment developer with a buy rating.

Its price target of $320 suggests shares could rally 25% from Tuesday's close. "Amgen is a best-in-class operator with high margins and a strong history of protecting its assets. While some very old products are finally facing patent cliffs it will likely be gradual and a broadened portfolio allows for continued growth," analyst Morten Herholdt wrote in a Wednesday note.

mountain AMGN in 2023 — CNBC's Michael Bloom contributed to this report.

 

Terima kasih atas komentar Anda. Komentar Anda akan dipublikasikan setelah ditinjau.
Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

 /  🏆 12. in İD

Indonesia Berita Terbaru, Indonesia Berita utama